FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Fluticasone propionate is a corticosteroid with anti-inflammatory activity; salmeterol xinafoate is a selective long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle.
| Metabolism | Fluticasone propionate is metabolized via CYP3A4; salmeterol xinafoate is metabolized primarily by hepatic CYP3A4. |
| Excretion | Fluticasone propionate is eliminated primarily via hepatic metabolism and fecal excretion; <5% excreted renally. Salmeterol xinafoate is predominantly eliminated via hepatic metabolism with ~25% excreted in feces and <10% in urine as unchanged drug. |
| Half-life | Fluticasone propionate: terminal half-life approximately 7.8 hours (range 6-10 hours) after inhalation; clinically supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-12 hours) after inhalation. |
| Protein binding | Fluticasone propionate: approximately 90% bound to plasma proteins (mainly albumin). Salmeterol: approximately 96% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Fluticasone propionate: Vd approximately 4.2 L/kg (range 2-10 L/kg); indicates extensive tissue distribution. Salmeterol: Vd approximately 7-15 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Fluticasone propionate: absolute oral bioavailability <1% due to extensive first-pass metabolism; inhaled dose has low systemic bioavailability (approximately 13-20% of delivered dose reaches systemic circulation, dependent on device). Salmeterol: oral bioavailability <5% due to first-pass metabolism; inhaled dose systemic bioavailability approximately 20-30% of delivered dose. |
| Onset of Action | Fluticasone propionate: not applicable for acute effects; onset of anti-inflammatory benefit requires days to weeks. Salmeterol: bronchodilation begins within 10-20 minutes after inhalation, with peak effect at 2-4 hours. |
| Duration of Action | Fluticasone propionate: duration of anti-inflammatory effect persists for at least 12 hours with regular use; supports twice-daily dosing. Salmeterol: bronchodilation lasts approximately 12 hours, supporting twice-daily dosing; not for acute rescue. |
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart. For patients not adequately controlled on lower doses, may increase to one inhalation of 250/50 or 500/50 twice daily.
| Dosage form | POWDER |
| Renal impairment | No specific dose adjustment required for renal impairment. Use with caution due to potential for systemic corticosteroid effects, but no GFR-based modifications established. |
| Liver impairment | Contraindicated in Child-Pugh Class C. For Child-Pugh Class A or B, use caution as salmeterol clearance may be reduced. Consider monitoring and starting at lowest available strength (100/50). No specific dose adjustment guidelines. |
| Pediatric use | For children aged 12 years and older: one inhalation twice daily. For children 4-11 years: one inhalation of lower strength (100/50) twice daily. Not recommended for children under 4 years. Weight-based dosing not established. |
| Geriatric use | No specific dose adjustment required. Use lowest effective dose due to increased risk of adverse events (e.g., osteoporosis, cataracts, glaucoma) from fluticasone. Monitor for systemic corticosteroid effects and consider bone mineral density screening. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other adrenergic drugs can have additive cardiovascular effects Can cause paradoxical bronchospasm and increase the risk of asthma-related death.
| Breastfeeding | Fluticasone propionate: L2 (limited data, probably compatible). Salmeterol: L3 (likely compatible). M/P ratio not available for fluticasone; for salmeterol, no data. Excretion into breast milk is likely low due to high protein binding and low oral bioavailability. Monitor infant for side effects. |
| Teratogenic Risk | Fluticasone propionate and salmeterol xinafoate: Inhaled corticosteroids and beta-agonists are not associated with major congenital malformations. For fluticasone, animal studies show some fetal effects at high doses, but human data do not indicate increased risk of malformations. For salmeterol, human data are limited; however, beta-agonists are generally considered low risk. No specific trimester risks identified; use if benefits outweigh risks. |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists increase the risk of asthma-related death. Therefore, fluticasone propionate and salmeterol xinafoate should only be used in patients with asthma not adequately controlled on other asthma-controller medications or whose disease severity clearly warrants initiation of both an inhaled corticosteroid and a long-acting beta2-adrenergic agonist.
| Common Effects | COPD |
| Serious Effects |
["Primary treatment of status asthmaticus or acute episodes of asthma or COPD","Hypersensitivity to any component of the product"]
| Precautions | ["Risk of asthma-related death","Serious cardiovascular events, including arrhythmias and hypertension","Hypersensitivity reactions including anaphylaxis","Increased risk of pneumonia in COPD patients","Reduction in bone mineral density with long-term use","Cushing's syndrome and adrenal suppression with excessive use"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal lung function, asthma control, and fetal growth (ultrasound for growth restriction with poorly controlled asthma). Assess for signs of systemic corticosteroid effects (e.g., adrenal suppression) if high doses used. |
| Fertility Effects | Fluticasone propionate and salmeterol xinafoate: No known adverse effects on fertility in humans. Animal studies show no significant impairment. |